EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

BioCina-EnGeneIC

More Like This

PR Newswire associated0

BioCina and NovaCina Merger Bolsters Global CDMO Industry

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

PR Newswire associated0

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

ViroCell Biologics Signs Master Services Agreement With Prominent NCI-Designated Cancer Center

AGC Biologics Honored by Customers and Industry Leaders for Excellence in Contract Development and Manufacturing

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

ViroCell Biologics Completes Oversubscribed Financing